Dr. Perez-Soler News
- Agennix Receives Special Protocol Assessment Approval From FDA For The Pivotal Trial Of Talactoferrin Alfa In ... Friday, January 18, 2008 @ 4:05AMAgennix Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase 3 trial evaluating its lead molecule, talactoferrin alfa, in combination with chemotherapy as first-line treatment in patients with non-small cell lung cancer (NSCLC) under the Special Protocol Assessment (SPA) process.
- Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in ... Thursday, January 17, 2008 @ 7:00AM Agennix Incorporated announced today that the U.S. Food and Drug Administration has approved the design of a single, pivotal, Phase 3 trial evaluating its lead molecule, talactoferrin alfa, in combination with chemotherapy as first-line treatment in patients with non-small cell lung cancer under the Special Protocol Assessment process.
